# South Korea Migraine Drugs Market > South Korea Migraine Drugs Market Research Report: Size, Share, Trend Analysis By End-User (Hospitals And Clinics, Retail Pharmacy, Online Pharmacy, Others), By Types (Episodic Migraine, Chronic Migraine), By Treatment Type (Acute, Preventive, Neuromodulation Devices) and By Drug Class (Triptans, Betablockers, Angiotensin Blockers, Tricyclics, Anticonvulsants) - Growth Outlook & Industry Forecast 2025 To 2035 - **Forecast Period:** 2025 - 2035 - **CAGR:** 3.72% - **2024:** $ 136.82 Million - **2025:** $ 141.91 Million - **2035:** $ 204.55 Million - **Key Players:** Amgen (US), Eli Lilly (US), Teva Pharmaceutical Industries (IL), Pfizer (US), Boehringer Ingelheim (DE), Novartis (CH), AbbVie (US), Alder BioPharmaceuticals (US), Zynerba Pharmaceuticals (US) **Report ID:** MRFR/MED/49252-HCR · **Pages:** 200 · **Author:** Nidhi Mandole & Rahul Gotadki · **Last Updated:** August 24, 2026 **URL:** https://www.marketresearchfuture.com/reports/south-korea-migraine-drugs-market-51009 --- ## Market Summary ## **South Korea Migraine Drugs Market Overview** As per MRFR analysis, the South Korea Migraine Drugs Market Size was estimated at 131.93 (USD Million) in 2023. The South Korea Migraine Drugs Market Industry is expected to grow from 136.75(USD Million) in 2024 to 215.91 (USD Million) by 2035. The South Korea Migraine Drugs Market CAGR (growth rate) is expected to be around 4.239% during the forecast period (2025 - 2035). **Key South Korea Migraine Drugs Market Trends Highlighted** The South Korea Migraine Drugs Market is experiencing a notable shift driven by several key market drivers. Increasing awareness about migraine as a serious health issue is prompting both healthcare providers and patients to seek effective treatments. South Korea's advanced healthcare system enables better access to various migraine medications, including preventive treatments and acute relief options. The rise in the number of migraine patients, especially among working-age adults, further drives the market as more individuals recognize the significance of timely and effective treatment for improving their quality of life.  Opportunities to be explored include the growing demand for personalized medicine.With advancements in biotechnology, pharmaceutical companies are focusing on developing targeted therapies that cater to the specific needs of patients with different migraine profiles. Additionally, the potential for expanding telemedicine services in South Korea can enhance patient engagement and facilitate timely prescriptions and consultations for those suffering from migraines.  Trends in recent times reflect an increasing emphasis on research and development efforts by South Korean pharmaceutical companies to create new migraine drugs. There is a growing interest in non-pharmacological treatments as well, such as cognitive behavioral therapy and biofeedback, indicating a more holistic approach to managing migraine.Moreover, the impact of lifestyle changes and stress management initiatives is gaining attention, in recognition of their role in migraine triggers. As South Korea continues to innovate and adapt in healthcare, the migraine drugs segment is poised for growth, driven by a combination of technological advancements and evolving patient needs. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review **South Korea Migraine Drugs Market Drivers** **Increasing Prevalence of Migraine Disorders in South Korea** The rising incidence of migraine disorders in the population is a major factor propelling the South Korea migraine drugs market. Approximately 15% of South Korean adults, or about 7 million people, have reported having migraines, according to the Korean National Health Insurance Service.  The need for efficient pharmaceutical remedies is being driven by the increase in migraine occurrence. In addition, the Korean government has put in place health programs to raise awareness and enhance migraine treatment. As more people look for treatment alternatives, the South Korea migraine drugs market is anticipated to grow as a result of the growing emphasis on enhancing healthcare access and education about migraines. **Advancements in Migraine Drug Formulations and Treatments** Innovations in drug formulations and therapies are providing new treatment options for migraine sufferers in South Korea. Recent advancements include the development of CGRP (Calcitonin Gene-Related Peptide) antagonists, which have shown high efficacy rates. Studies published by local pharmaceutical associations indicate that these new treatments have a success rate of up to 70% in reducing the frequency of migraines.  As a result, this is likely to expand the market opportunities for pharmaceutical companies, as clinicians increasingly adopt these new therapies for their patients.Leading companies like Dong-A ST and Hanmi Pharmaceutical are actively investing in Research and Development (R&D) to further enhance treatment options in the South Korea Migraine Drugs Market Industry. **Government Initiatives and Support for Migraine Research** The South Korean government has initiated various programs to support Research and Development (R&D) in the field of migraine treatment. With a focus on reducing the socio-economic burden posed by chronic illnesses, funding for migraine research has seen a marked increase. The South Korean Ministry of Health and Welfare has allocated significant resources towards understanding chronic pain and improving treatment modalities through public health policies. Furthermore, collaboration between academic institutions and pharmaceutical companies is encouraged, with initiatives aimed at fostering innovation in the South Korean Migraine Drugs Market Industry. Such government initiatives translate to more robust market growth as newer therapies enter the pharmaceutical pipeline. **South Korea Migraine Drugs Market Segment Insights** **Migraine Drugs Market End-User Insights** The South Korea Migraine Drugs Market exhibits a diverse range of End-User platforms pivotal for the distribution and accessibility of migraine medications. The sector encompasses Hospitals and Clinics, Retail Pharmacies, Online Pharmacies, and Other channels, each contributing significantly to the overall dynamics of the industry. Hospitals and Clinics serve as primary healthcare touchpoints, where a considerable volume of migraine treatments are prescribed and administered.  The professional healthcare setting facilitates patient evaluations and broader treatments, often leading to increased patient engagement and satisfaction with care. Moreover, hospitals and clinics are instrumental in the initial diagnosis and ongoing management of migraine patients, leveraging the expertise of specialized neurologists.Retail Pharmacies remain a critical part of the South Korea Migraine Drugs Market as they provide convenience and accessibility to a wider segment of the population.  This sector benefits from the growing consumer trend towards swift access to medications, allowing patients to obtain their prescribed migraine drugs directly in their neighborhood. The personal interaction with pharmacists further enhances patient trust and adherence to treatment regimens. Additionally, the rise in collaborations between retail pharmacies and healthcare providers has led to greater awareness and education about migraine treatments among the general public.In the digital era, Online Pharmacies have carved out an essential niche within the market, showcasing a transformative shift in how patients procure medications.  The convenience of online ordering, combined with home delivery options, addresses the preferences of a technology-savvy demographic. The omnipresence of digital platforms supports the overall growth of the South Korea Migraine Drugs Market by catering to the demands of patients seeking discretion and ease of access. This segment has significantly impacted patients' decision-making processes, with many opting for online solutions due to the increasing comfort and trust in e-commerce.Furthermore, Other channels encompass various distribution methods, including telehealth services and community health initiatives designed to raise awareness about migraine management and treatment options.  The diversification of distribution avenues not only reflects the evolving landscape of healthcare access but also ensures that various patient preferences and needs are met, ultimately enhancing treatment adherence and health outcomes. Collectively, these End-User segments contribute to shaping the South Korea Migraine Drugs Market, as they address the complexities associated with migraine care through multifaceted approaches that prioritize patient accessibility, education, and convenience in medication procurement. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review **Migraine Drugs Market Type Insights** The South Korea [Migraine Drugs Market](../../../reports/migraine-drugs-market-8379) is categorized by Type, including dominant categories such as Episodic Migraine and Chronic Migraine. The South Korea experiences a significant prevalence of migraines, with the episodic form being common among individuals with occasional headaches, typically occurring less than fifteen days a month. Conversely, the chronic migraine segment represents a critical area of concern, affecting those who endure migraines on more than fifteen days per month, leading to substantial impacts on their quality of life and productivity.Given the increasing awareness about migraine management and the introduction of advanced therapeutics, there is considerable growth potential in these areas.  Further, the South Korean population’s focus on healthcare advancements, coupled with rising healthcare expenditures, supports the ongoing development and enhancement of migraine drug therapies, especially for chronic migraine, which requires more intensive treatment protocols. The significance of these segments is accentuated by the rising demand for effective treatment options, driven by lifestyle changes, stress, and environmental factors, ultimately driving growth in the South Korea Migraine Drugs Market.The challenge remains in addressing the therapy gaps, particularly for chronic migraine patients, as research and development focused on novel treatment modalities is essential in improving patient outcomes in South Korea. **Migraine Drugs Market Treatment Type Insights** The South Korea Migraine Drugs Market is significantly segmented into various treatment types, notably Acute, Preventive, and Neuromodulation Devices. Acute treatments primarily focus on providing immediate relief during a migraine attack, catering to the needs of patients experiencing sudden, debilitating pain. Preventive treatments, on the other hand, aim to reduce the frequency and severity of migraine episodes, playing a crucial role in long-term management for chronic sufferers. With an increasing prevalence of migraine cases in South Korea, the demand for effective preventive options is notable, reflecting an evolving landscape in patient care. Neuromodulation Devices represent a growing trend with innovative technologies offering non-pharmacological approaches to migraine management, appealing to patients who may prefer to avoid medication. The combination of these treatment types addresses the varying needs of migraine sufferers, contributing to a comprehensive strategy for alleviating the burden of this disorder. The rise in healthcare awareness, increasing access to advanced medical technologies, and the expanding pharmaceutical portfolios are propelling the growth of these treatment options in the region, driving the momentum in the South Korea Migraine Drugs Market. **Migraine Drugs Market Drug Class Insights** The South Korea Migraine Drugs Market is segmented by drug class, encompassing various categories like Triptans, Betablockers, Angiotensin Blockers, Tricyclics, and Anticonvulsants. Triptans are notable for their ability to provide quick relief from migraine attacks, making them a preferred choice among patients. Betablockers, historically used for hypertension and heart issues, have gained traction in migraine prevention due to their efficacy in reducing attack frequency. Angiotensin Blockers, although less commonly used, show potential in addressing migraine symptoms linked to vascular activity.Tricyclics, often assisting in both pain management and mood stabilization, are recognized for their role in chronic migraine treatment.  Lastly, Anticonvulsants have emerged as vital players in migraine prophylaxis, offering dual benefits by managing seizure disorders and migraines alike. The increasing recognition of these drugs in both treating and preventing migraines, coupled with ongoing research initiatives within South Korea, is expected to drive further innovation in the sector. Furthermore, the growing incidence of migraines among the population underscores the importance and relevance of these drug classes in addressing this prevalent health issue effectively. **South Korea Migraine Drugs Market Key Players and Competitive Insights** The South Korea Migraine Drugs Market has displayed significant growth in recent years, driven by increasing awareness and improved diagnosis rates of migraine among the population. The competitive landscape in this market is marked by a mix of global pharmaceutical giants and local players, all vying for a share in this lucrative sector. A multitude of offerings exists in the market, ranging from over-the-counter medications to specialized prescription drugs, catering to the diverse needs of patients suffering from migraines. The evolving regulatory environment, along with advancements in drug formulations and delivery systems, enhances the competitive dynamics.  As a result, companies are focusing on innovative solutions and strategic partnerships to solidify their positions in the marketplace.Teva Pharmaceutical has established a robust presence in the South Korean Migraine Drugs Market, offering a wide range of products that cater to the various needs of migraine sufferers. The company’s strength lies in its extensive portfolio, including both generics and specialty drugs, which helps to make treatments more accessible and affordable. Teva's commitment to research and development further enhances its competitive edge, as it continuously strives to improve existing formulations and develop new innovative therapies specifically aimed at migraine relief.  The company's established distribution networks in South Korea enable it to reach a broad audience, providing strong support for its product lines and maintaining a loyal customer base. Teva's reputation for quality and efficacy in its migraine treatments reinforces its credibility in the market.Pfizer plays a pivotal role in the South Korea Migraine Drugs Market with its innovative offerings and strategic positioning. The company is known for its flagship products targeting migraine treatments, which are highly regarded for efficacy among healthcare professionals and patients alike. Pfizer's strengths include a strong research-driven approach that has led to successful drug development and effective therapies designed specifically for migraine relief.  The company's presence in South Korea is bolstered by comprehensive marketing strategies and collaborations with healthcare providers, ensuring broad accessibility to its products. Furthermore, Pfizer’s engagement in potential mergers and acquisitions has strengthened its portfolio and market presence, facilitating the introduction of novel solutions for migraine sufferers. This strategic focus positions Pfizer as a key player in the South Korean market, making significant contributions to migraine therapy advancements. **Key Companies in the South Korea Migraine Drugs Market Include:** - [**Teva Pharmaceutical**](https://ir.tevapharm.com/news-and-events/press-releases/press-release-details/2024/Teva-Confirms-Efficacy-and-Safety-of-AJOVY-fremanezumab-for-the-Prevention-of-Migraine-With-Results-from-Phase-3-Trial-in-China/default.aspx) - Pfizer - Boehringer Ingelheim - Mylan - Merck - GlaxoSmithKline - Roche - AstraZeneca - Sumitomo Dainippon Pharma - Eli Lilly - Johnson & Johnson - AbbVie - Amgen - Novartis - Sanofi **South Korea Migraine Drugs Market Industry Developments** The South Korea Migraine Drugs Market has been experiencing notable developments in recent months. Teva Pharmaceutical and AbbVie are currently focusing on expanding their product offerings, with recent launches aimed at enhancing treatment options for chronic migraine sufferers. In October 2023, Pfizer announced strategic partnerships aimed at increasing the accessibility of its migraine treatments within local markets. Meanwhile, there has been significant growth reported among companies such as Eli Lilly and Johnson and Johnson, which are leveraging innovative treatments to capture market share.  In terms of mergers and acquisitions, no recent notable transactions have been recorded for the listed companies in the South Korea Migraine Drugs Market, as various companies continue to strengthen their existing research and product lines instead. Over the past few years, regulatory reforms in South Korea have paved the way for quicker approvals of new migraine therapies, consequently impacting market dynamics positively.  Furthermore, a growing awareness regarding migraine management among healthcare professionals and patients alike has contributed to a wider adoption of preventive therapies within the region. This evolving landscape underscores the increasing importance of migraine treatment in the South Korean healthcare market. **South Korea Migraine Drugs Market Segmentation Insights** **Migraine Drugs Market End-User Outlook** - Hospitals And Clinics - Retail Pharmacy - Online Pharmacy - Others **Migraine Drugs Market Type Outlook** - Episodic Migraine - Chronic Migraine **Migraine Drugs Market Treatment Type Outlook** - Acute - Preventive - Neuromodulation Devices **Migraine Drugs Market Drug Class Outlook** - Triptans - Betablockers - Angiotensin Blockers - Tricyclics - Anticonvulsants ## Market Drivers ### Rising Healthcare Expenditure The increase in healthcare expenditure in South Korea is a vital driver for the migraine drugs market. As the government and private sectors allocate more funds towards healthcare, patients gain better access to medical services and treatments. This trend is particularly relevant for migraine sufferers, who often require ongoing treatment and management strategies. The rise in healthcare spending has also led to improved insurance coverage for migraine medications, making them more affordable for patients. Consequently, the migraine drugs market is likely to benefit from this trend, as more individuals seek effective treatments for their migraine conditions, ultimately enhancing their quality of life. ### Growing Awareness and Education In South Korea, increasing awareness and education regarding migraine disorders are pivotal in shaping the migraine drugs market. Public health campaigns and educational initiatives by healthcare professionals have contributed to a better understanding of migraine symptoms and treatment options. This heightened awareness encourages individuals to seek medical help, leading to an uptick in prescriptions for migraine medications. Moreover, the availability of information through digital platforms has empowered patients to engage in discussions about their treatment options with healthcare providers. As a result, the migraine drugs market is likely to experience growth, as more patients are diagnosed and treated effectively, reducing the burden of this condition on society. ### Increasing Incidence of Migraine The rising incidence of migraine in South Korea is a crucial driver for the migraine drugs market. Recent studies indicate that approximately 10% of the population experiences migraines, with a notable prevalence among women aged 18-44. This growing patient base necessitates effective treatment options, thereby propelling demand for various migraine medications. The increasing awareness of migraine as a significant health issue has led to more individuals seeking medical advice and treatment. Consequently, pharmaceutical companies are focusing on developing innovative drugs to cater to this expanding market. The migraine drugs market is likely to witness substantial growth as healthcare providers emphasize the importance of addressing this debilitating condition, which can severely impact quality of life and productivity. ### Regulatory Support for New Treatments Regulatory support for the approval of new migraine treatments is a significant driver for the migraine drugs market. The South Korean government has streamlined the drug approval process, facilitating quicker access to innovative therapies for patients. This supportive regulatory environment encourages pharmaceutical companies to invest in the development of new migraine medications, knowing that they can bring their products to market more efficiently. Additionally, the government's focus on improving healthcare access and outcomes aligns with the need for effective migraine treatments. As a result, the migraine drugs market is poised for growth, with an increasing number of new therapies expected to enter the market in the coming years. ### Advancements in Pharmaceutical Research Innovations in pharmaceutical research are significantly influencing the migraine drugs market. The development of new drug formulations and delivery methods has enhanced treatment efficacy and patient compliance. For instance, the introduction of CGRP inhibitors has revolutionized migraine management, providing patients with more effective preventive options. Furthermore, ongoing clinical trials in South Korea are exploring novel therapeutic targets, which may lead to the approval of additional migraine medications. This dynamic research environment fosters competition among pharmaceutical companies, driving them to invest in R&D to capture market share. As a result, the migraine drugs market is expected to expand, with a diverse range of treatment options becoming available to patients. ## Future Outlook The [Migraine Drugs Market](https://www.marketresearchfuture.com/reports/migraine-drugs-market-8379) is projected to grow at a 3.72% CAGR from 2025 to 2035, driven by increasing prevalence and advancements in drug formulations. **New opportunities:** - Development of personalized migraine treatment plans - Expansion of telehealth services for migraine management - Investment in AI-driven drug discovery platforms By 2035, the market is expected to achieve substantial growth and innovation. ## Segment Insights ### By Type: Triptans (Largest) vs. CGRP Inhibitors (Fastest-Growing) The South Korea migraine drugs market displays a diverse landscape across its segment types, with Triptans leading in market share due to their established efficacy and broad patient acceptance. Abortive Drugs form a substantial portion of the market, catering to immediate migraine relief needs, while Preventive Drugs are steadily gaining traction among patients looking for long-term solutions. CGRP Inhibitors, while currently a smaller segment, are rapidly increasing their presence as innovative treatment options become sought after. Growth trends in the South Korea migraine drugs market are influenced by increasing awareness of chronic migraines and the importance of effective treatment. The shift towards personalized medicine and the development of novel drugs are expected to drive momentum, especially for CGRP Inhibitors, which offer a new mode of action. Additionally, favorable healthcare policies and improved access to these treatments will support expansion, making it a dynamic arena for pharmaceutical innovation. Triptans: Dominant vs. CGRP Inhibitors: Emerging Triptans hold a dominant position in the South Korea migraine drugs market, characterized by their rapid action and substantial patient reliance for alleviating acute migraine episodes. They are frequently the first-line treatment preferred by healthcare professionals for their effectiveness and the trust they have built within the patient community. On the other hand, CGRP Inhibitors represent the emerging front with their innovative mechanism that has demonstrated promise in both acute and preventive treatment. Their growing acceptance is coupled with robust clinical data, indicating high efficacy and reduced side effects, which attract a new patient demographic seeking alternatives to traditional therapies. ### By Route of Administration: Oral (Largest) vs. Injectable (Fastest-Growing) In the South Korea migraine drugs market, the distribution of market share reveals that oral administration holds the largest share, largely favored by patients for its convenience and ease of use. Injectable forms, while currently smaller in share, are gaining traction as they offer rapid relief for acute migraine attacks, appealing to a specific segment of patients seeking immediate alleviation. Meanwhile, nasal formulations are present but play a niche role compared to the dominant oral and emerging injectable categories. The growth trends for the route of administration segment are heavily driven by advancements in pharmaceutical formulations and patient preference shifts. Oral drugs continue to dominate due to their established presence and user accessibility. However, the injectable route is experiencing robust growth, particularly among patients looking for quick pain relief. The rise in innovative injectable solutions is set to enhance their market presence and acceptance, paving the way for an evolving landscape in migraine management. Oral (Dominant) vs. Injectable (Emerging) Oral administration remains the dominant route in the South Korea migraine drugs market, primarily because of its convenience, patient compliance, and established efficacy. Many patients prefer oral medications as they can be easily self-administered at home without medical supervision. In contrast, the injectable route is emerging as an increasingly popular option due to the need for faster-acting medications that provide immediate relief from acute migraine episodes. While injectables require healthcare professional involvement for administration, their effectiveness is driving a formidable user base among those suffering from more severe migraine attacks. As the market evolves, both routes are expected to coexist, with oral medications addressing general needs and injectables catering to those requiring rapid intervention. ### By Therapeutic Class: Beta Blockers (Largest) vs. Antidepressants (Fastest-Growing) In the South Korea migraine drugs market, the distribution of market shares among the therapeutic classes reveals that Beta Blockers hold a significant share, positioning them as the largest segment. This is followed closely by NSAIDs and Ergots, which also have notable contributions, although not as dominant. Antidepressants, while smaller in market share, are gaining traction as they are increasingly recognized for their effectiveness in migraine management. The growth trends within this segment are driven by a rising awareness among healthcare professionals regarding the off-label uses of certain drugs, particularly Antidepressants. Moreover, ongoing research into the efficacy of Ergots and NSAIDs continues to propel their use, while Beta Blockers remain a reliable choice due to their established status. The increase in migraine prevalence and the development of new formulations also contribute to the evolving dynamics of these therapeutic classes. Beta Blockers (Dominant) vs. Antidepressants (Emerging) Beta Blockers are recognized as the dominant force in the South Korea migraine drugs market. Their effectiveness in preventing migraines is well established, and they are often the first-line treatment choice for many patients. Their ability to manage comorbid conditions such as hypertension adds to their appeal. In contrast, Antidepressants represent an emerging segment, gaining attention for their off-label use in migraine management. These medications are particularly appealing due to their potential to address coexisting mood disorders in patients with migraines, making them a multifaceted treatment option. As clinical guidelines evolve and more practitioners become aware of the benefits of Antidepressants, their market share is expected to expand significantly. ### By Patient Demographics: Adults (Largest) vs. Children (Fastest-Growing) In the South Korea migraine drugs market, the demographic distribution reveals that adults constitute the largest segment, accounting for a significant share of the overall market due to the higher incidence of migraine among this age group. Conversely, children represent the fastest-growing demographic, driven by increasing awareness of migraine conditions and better diagnosis in younger patients. This shift highlights an evolving landscape where treatment options are becoming more tailored to varying age groups. Growth trends in this segment are buoyed by a surge in targeted therapies designed for specific age demographics, particularly in pediatric care. The increasing prevalence of migraine in children has prompted pharmaceutical companies to innovate, focusing on formulations suitable for younger patients. Simultaneously, the adult segment continues to thrive with ongoing advancements in treatment technologies and patient-centric approaches, ensuring sustained engagement and market expansion. Adults: Dominant vs. Children: Emerging The adult segment remains the dominant player in the South Korea migraine drugs market, characterized by a broad selection of medications tailored to various severity levels and individual patient needs. This demographic benefits from extensive clinical research, which addresses diverse migraine triggers and treatment responses. On the other hand, the children segment is emerging, spurred by increased prevalence recognition and a growing demand for age-appropriate therapies. As healthcare providers become more adept at diagnosing and treating migraines in children, the market is witnessing innovative drug formulations that cater specifically to pediatric patients. This dual focus ensures that both segments receive the necessary attention from manufacturers, fostering a competitive yet supportive market environment. ## Competitive Benchmarking The migraine drugs market in South Korea is characterized by a competitive landscape that is increasingly shaped by innovation and strategic partnerships. Key players such as Amgen (US), Eli Lilly (US), and Teva Pharmaceutical Industries (IL) are actively pursuing growth through a combination of product development and market expansion. Amgen (US) has focused on enhancing its portfolio with novel therapies, while Eli Lilly (US) emphasizes strategic collaborations to bolster its research capabilities. Teva Pharmaceutical Industries (IL) appears to be concentrating on optimizing its supply chain to ensure efficient distribution of its migraine treatments, thereby enhancing its market presence. Collectively, these strategies indicate a dynamic environment where innovation and operational efficiency are paramount.In terms of business tactics, companies are increasingly localizing manufacturing to reduce costs and improve responsiveness to market demands. The competitive structure of the market is moderately fragmented, with several players vying for market share. This fragmentation allows for diverse treatment options, yet it also intensifies competition among key players, compelling them to differentiate through unique value propositions. In October Eli Lilly (US) announced a strategic partnership with a local biotech firm to co-develop a new migraine treatment. This collaboration is significant as it not only enhances Eli Lilly's research capabilities but also allows for localized insights into patient needs, potentially leading to more effective therapies. Such partnerships are likely to accelerate the development timeline and improve market penetration. In September Teva Pharmaceutical Industries (IL) launched a new digital health platform aimed at improving patient adherence to migraine treatment regimens. This initiative underscores the growing trend of integrating technology into healthcare solutions, which may enhance patient outcomes and foster brand loyalty. By leveraging digital tools, Teva is positioning itself as a forward-thinking player in the market, likely appealing to tech-savvy consumers. In August Amgen (US) expanded its manufacturing capabilities in South Korea, investing approximately $50 million in a new facility. This move is indicative of Amgen's commitment to meeting local demand and ensuring a reliable supply of its migraine therapies. Such investments not only enhance operational efficiency but also signal confidence in the growth potential of the South Korean market. As of November current trends in the migraine drugs market are increasingly defined by digitalization, sustainability, and the integration of artificial intelligence (AI) in drug development. Strategic alliances are becoming more prevalent, allowing companies to pool resources and expertise to drive innovation. Looking ahead, competitive differentiation is likely to evolve from traditional price-based strategies to a focus on technological advancements and supply chain reliability. This shift may redefine how companies approach market entry and product development, emphasizing the importance of agility and responsiveness in a rapidly changing landscape. ## Recent News & Developments The South Korea Migraine Drugs Market has been experiencing notable developments in recent months. Teva Pharmaceutical and AbbVie are currently focusing on expanding their product offerings, with recent launches aimed at enhancing treatment options for chronic migraine sufferers. In October 2023, Pfizer announced strategic partnerships aimed at increasing the accessibility of its migraine treatments within local markets. Meanwhile, there has been significant growth reported among companies such as Eli Lilly and Johnson and Johnson, which are leveraging innovative treatments to capture market share.  In terms of mergers and acquisitions, no recent notable transactions have been recorded for the listed companies in the South Korea Migraine Drugs Market, as various companies continue to strengthen their existing research and product lines instead. Over the past few years, regulatory reforms in South Korea have paved the way for quicker approvals of new migraine therapies, consequently impacting market dynamics positively.  Furthermore, a growing awareness regarding migraine management among healthcare professionals and patients alike has contributed to a wider adoption of preventive therapies within the region. This evolving landscape underscores the increasing importance of migraine treatment in the South Korean healthcare market. ## Report Scope | MARKET SIZE 2024 | 136.82(USD Million) | | --- | --- | | MARKET SIZE 2025 | 141.91(USD Million) | | MARKET SIZE 2035 | 204.55(USD Million) | | COMPOUND ANNUAL GROWTH RATE (CAGR) | 3.72% (2025 - 2035) | | REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends | | BASE YEAR | 2024 | | Market Forecast Period | 2025 - 2035 | | Historical Data | 2019 - 2024 | | Market Forecast Units | USD Million | | Key Companies Profiled | Amgen (US), Eli Lilly (US), Teva Pharmaceutical Industries (IL), Pfizer (US), Boehringer Ingelheim (DE), Novartis (CH), AbbVie (US), Alder BioPharmaceuticals (US), Zynerba Pharmaceuticals (US) | | Segments Covered | Type, Route of Administration, Therapeutic Class, Patient Demographics | | Key Market Opportunities | Emerging biologics and digital therapeutics present new avenues in the migraine drugs market. | | Key Market Dynamics | Rising demand for innovative migraine therapies drives competition and regulatory scrutiny in South Korea's migraine drugs market. | | Countries Covered | South Korea | ## Frequently Asked Questions **Q: What was the overall market valuation of the migraine drugs market in 2024?** A: The overall market valuation was $136.82 Million in 2024. **Q: What is the projected market valuation for the migraine drugs market in 2035?** A: The projected valuation for 2035 is $204.55 Million. **Q: What is the expected CAGR for the migraine drugs market during the forecast period 2025 - 2035?** A: The expected CAGR for the market during the forecast period 2025 - 2035 is 3.72%. **Q: Which companies are considered key players in the migraine drugs market?** A: Key players include Amgen, Eli Lilly, Teva Pharmaceutical Industries, Pfizer, Boehringer Ingelheim, Novartis, AbbVie, Alder BioPharmaceuticals, and Zynerba Pharmaceuticals. **Q: What were the valuations for abortive and preventive drugs in 2024?** A: In 2024, abortive drugs were valued at $30.0 - $45.0 Million, while preventive drugs were valued at $40.0 - $60.0 Million. **Q: How do the valuations of CGRP inhibitors and triptans compare in 2024?** A: CGRP inhibitors were valued at $25.0 - $40.0 Million, whereas triptans had a higher valuation of $41.82 - $59.55 Million in 2024. **Q: What were the market valuations for oral, injectable, and nasal routes of administration in 2024?** A: In 2024, oral routes were valued at $68.41 - $104.0 Million, injectables at $41.09 - $62.0 Million, and nasal routes at $27.32 - $38.55 Million. **Q: What is the market valuation for NSAIDs and antidepressants in 2024?** A: NSAIDs were valued at $30.0 - $45.0 Million, while antidepressants had a higher valuation of $46.82 - $69.55 Million in 2024. **Q: How does the market for migraine drugs differ among various patient demographics?** A: In 2024, the market for adults was valued at $82.0 - $123.0 Million, while children and geriatrics were valued at $30.0 - $45.0 Million and $24.82 - $36.55 Million, respectively. **Q: What trends are expected in the migraine drugs market as it approaches 2035?** A: As the market approaches 2035, it is likely to experience growth driven by an increasing focus on innovative treatments and a projected valuation increase to $204.55 Million. --- *This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/south-korea-migraine-drugs-market-51009*